Fig. 8From: Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinomaHE staining and FH staining of PRCC2 (A, B). Representative images of low and high TPX2 expression in sPRCC2 (C, D). Overall survival curve and progression-free survival of TPX2 expression in FUSCC cohort (E–F). Progression-free survival curve of sPRCC2 patients treated with Everolimus in FUSCC cohort (G). Progression-free survival curve of high risk sPRCC2 patients treated with Sunitinib or Everolimus (H). Tumor reduction image of sPRCC2 patients in FUSCC cohortBack to article page